Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development: Part 3—Introduction to Pharmacodynamic Modeling Methods

Population pharmacodynamic (PD) models describe the time course of drug effects, relating exposure to response, and providing a more robust understanding of drug action than single assessments. PD models can test alternative dose regimens through simulation, allowing for informed assessment of potential dose regimens and study designs. This is the third paper in a three‐part series, providing an introduction into methods for developing and evaluating population PD models. Example files are available in the Supplementary Data .

[1]  D. Rubin,et al.  On Jointly Estimating Parameters and Missing Data by Maximizing the Complete-Data Likelihood , 1983 .

[2]  Andrew C. Hooker,et al.  Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models , 2011, The AAPS Journal.

[3]  D R Mould,et al.  Model‐Based Meta‐Analysis: An Important Tool for Making Quantitative Decisions During Drug Development , 2012, Clinical pharmacology and therapeutics.

[4]  P. Deb.  Finite Mixture Models , 2008 .

[5]  M. Jamei,et al.  Predicting drug–drug interactions: application of physiologically based pharmacokinetic models under a systems biology approach , 2013, Expert review of clinical pharmacology.

[6]  Diane R Mould,et al.  Population Pharmacokinetic‐Pharmacodynamic Modeling of Biological Agents: When Modeling Meets Reality , 2010, Journal of clinical pharmacology.

[7]  A S Perelson,et al.  Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. , 1998, Science.

[8]  Bill Frame,et al.  Mixture Modeling with NONMEM V , 2006 .

[9]  Gary M. Pollack,et al.  Opioid Tolerance Development: A Pharmacokinetic/Pharmacodynamic Perspective , 2008, The AAPS Journal.

[10]  Marc Lavielle,et al.  Between-Subject and Within-Subject Model Mixtures for Classifying HIV Treatment Response , 2012 .

[11]  D Winne,et al.  [Receptor theory in pharmacology]. , 1967, Die Medizinische Welt.

[12]  Varun Garg,et al.  Comparison of four basic models of indirect pharmacodynamic responses , 1993, Journal of Pharmacokinetics and Biopharmaceutics.

[13]  Wojciech Krzyzanski,et al.  Population Modeling of Filgrastim PK‐PD in Healthy Adults Following Intravenous and Subcutaneous Administrations , 2010, Journal of clinical pharmacology.

[14]  Lewis B. Sheiner,et al.  Simultaneous vs. Sequential Analysis for Population PK/PD Data I: Best-Case Performance , 2003, Journal of Pharmacokinetics and Pharmacodynamics.

[15]  Richard R. Almon,et al.  Quantitative Dynamic Models of Arthritis Progression in the Rat , 2008, Pharmaceutical Research.

[16]  Ruy M Ribeiro,et al.  Modeling HCV kinetics under therapy using PK and PD information. , 2009, Expert opinion on drug metabolism & toxicology.

[17]  L B Sheiner,et al.  The population approach to pharmacokinetic data analysis: rationale and standard data analysis methods. , 1984, Drug metabolism reviews.

[18]  David C. Heilbron,et al.  Zero-Altered and other Regression Models for Count Data with Added Zeros , 1994 .

[19]  F. Scheer,et al.  Organization of circadian functions: interaction with the body. , 2006, Progress in brain research.

[20]  E Niclas Jonsson,et al.  More efficient clinical trials through use of scientific model‐based statistical tests , 2002, Clinical pharmacology and therapeutics.

[21]  D. Rubin.  INFERENCE AND MISSING DATA , 1975 .

[22]  G Levy,et al.  Kinetics of drug action: an overview. , 1986, The Journal of allergy and clinical immunology.

[23]  A Sibbald,et al.  A pharmacodynamic model for pancuronium. , 1978, British journal of anaesthesia.

[24]  L B Sheiner,et al.  Learning versus confirming in clinical drug development , 1997, Clinical pharmacology and therapeutics.

[25]  Kazuya Maeda,et al.  Hepatic and intestinal drug transporters: prediction of pharmacokinetic effects caused by drug-drug interactions and genetic polymorphisms. , 2013, Annual review of pharmacology and toxicology.

[26]  M. Egorin,et al.  Pharmacodynamic model of topotecan-induced time course of neutropenia. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  L B Sheiner,et al.  Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. , 1980, Clinical pharmacology and therapeutics.

[28]  Timothy Goggin,et al.  A semimechanistic and mechanistic population PK-PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis. , 2004, British journal of clinical pharmacology.

[29]  Lewis B. Sheiner,et al.  Evaluation of methods for estimating population pharmacokinetic parameters. I. Michaelis-menten model: Routine clinical pharmacokinetic data , 1980, Journal of Pharmacokinetics and Biopharmaceutics.

[30]  D R Mould,et al.  Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development—Part 2: Introduction to Pharmacokinetic Modeling Methods , 2013, CPT: pharmacometrics & systems pharmacology.

[31]  Yifeng Lu,et al.  Quantitative PK–PD Model-Based Translational Pharmacology of a Novel Kappa Opioid Receptor Antagonist Between Rats and Humans , 2011, The AAPS Journal.

[32]  G. Levy,et al.  Kinetics of pharmacologic effects in man: The anticoagulant action of warfarin , 1969, Clinical pharmacology and therapeutics.

[33]  G. Levy,et al.  RELATIONSHIP BETWEEN ELIMINATION RATE OF DRUGS AND RATE OF DECLINE OF THEIR PHARMACOLOGIC EFFECTS. , 1964, Journal of pharmaceutical sciences.

[34]  Kyle John Wilby,et al.  Review of boceprevir and telaprevir for the treatment of chronic hepatitis C. , 2012, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[35]  D R Mould,et al.  Using Disease Progression Models as a Tool to Detect Drug Effect , 2007, Clinical pharmacology and therapeutics.

[36]  Shiew-Mei Huang,et al.  The utility of modeling and simulation in drug development and regulatory review. , 2013, Journal of pharmaceutical sciences.

[37]  David J Doolette,et al.  A quantitative alternative to the hysteresis plot for measurement of drug transit time. , 2002, Journal of pharmacological and toxicological methods.

[38]  Ruud M Buijs,et al.  The Biological Clock: The Bodyguard of Temporal Homeostasis , 2004, Chronobiology international.

[39]  T. Kenakin.  Principles: receptor theory in pharmacology. , 2004, Trends in pharmacological sciences.

[40]  J. Bruhn,et al.  Pharmacodynamic Interaction between Propofol and Remifentanil Regarding Hypnosis, Tolerance of Laryngoscopy, Bispectral Index, and Electroencephalographic Approximate Entropy , 2004, Anesthesiology.

[41]  L E Friberg,et al.  An Agonist–Antagonist Interaction Model for Prolactin Release Following Risperidone and Paliperidone Treatment , 2009, Clinical pharmacology and therapeutics.

[42]  D. Mould,et al.  Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon alfa‐2a and a polyethylene glycol‐modified derivative in healthy subjects , 1996, Clinical pharmacology and therapeutics.

[43]  A. Hill,et al.  The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves , 1910 .

[44]  D R Mould,et al.  Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development , 2012, CPT: pharmacometrics & systems pharmacology.

[45]  Lewis B. Sheiner,et al.  Analyzing Multi-Response Data Using Forcing Functions , 2005, Journal of Pharmacokinetics and Pharmacodynamics.

[46]  Mats O Karlsson,et al.  Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  D R Mould,et al.  Simultaneous modeling of the pharmacokinetics and pharmacodynamics of midazolam and diazepam , 1995, Clinical pharmacology and therapeutics.

[48]  Matthew M. Hutmacher,et al.  Joint modeling of dizziness, drowsiness, and dropout associated with pregabalin and placebo treatment of generalized anxiety disorder , 2009, Journal of Pharmacokinetics and Pharmacodynamics.

[49]  Mark E. Sale,et al.  A Joint Model for Nonlinear Longitudinal Data with Informative Dropout , 2003, Journal of Pharmacokinetics and Pharmacodynamics.

[50]  Erik Olofsen,et al.  Response Surface Modeling of Remifentanil–Propofol Interaction on Cardiorespiratory Control and Bispectral Index , 2003, Anesthesiology.

[51]  R. Hansen,et al.  Properties of a general PK/PD model of antibody-ligand interactions for therapeutic antibodies that bind to soluble endogenous targets , 2010, mAbs.

[52]  W J Jusko,et al.  Precursor-dependent indirect pharmacodynamic response model for tolerance and rebound phenomena. , 1998, Journal of pharmaceutical sciences.

[53]  Lars Arendt-Nielsen,et al.  Pharmacokinetic/pharmacodynamic relationships of transdermal buprenorphine and fentanyl in experimental human pain models. , 2011, Basic & clinical pharmacology & toxicology.